display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - all populationmUC - M - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone JAVELIN Bladder 100 ... JAVELIN Bladder 100 ...

Study type: